Human erythrovirus B19 and blood transfusion - An update

Transfusion Medicine

Volumn 17, Issue 4, 2007, Pages 263-278

  Parsyan, A ^a,b   Candotti, D ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

B19; Blood donors; Human erythrovirus; Parvovirus; Transfusion; Transplantation

Indexed keywords

B19 VACCINE; IMMUNOGLOBULIN; UNCLASSIFIED DRUG; VIRUS VACCINE;

BLOOD COMPONENT; BLOOD TRANSFUSION; ERYTHEMA INFECTIOSUM; GAMMA IRRADIATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; NANOFILTRATION; ORGAN TRANSPLANTATION; PARVOVIRUS; PATHOGENESIS; PATIENT SAFETY; PREVALENCE; REVIEW; SERODIAGNOSIS; SEROPREVALENCE; TREATMENT PLANNING; VIREMIA; VIROLOGY; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS TRANSMISSION;

BLOOD DONORS; DNA, VIRAL; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; SEROLOGIC TESTS; TRANSPLANTATION; TRANSPLANTS; VIREMIA;

EID: 34547563256     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/j.1365-3148.2007.00765.x     Document Type: Review

References (128)

1. Anderson, L.J., Tsou, C., Parker, R.A., Chorba, T.L., Wulff, H., Tattersall, P. Mortimer, P.P 1986) Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. Journal of Clinical Microbiology 24, 522 526.
2. Arnold, D.M., Neame, P.B., Meyer, R.M. et al 2005) Autologous peripheral blood progenitor cells are a potential source of parvovirus B19 infection. Transfusion 45, 394 398.
3. Aubin, J.T., Defer, C., Vidaud, M., Maniez Montreuil, M. Flan, B 2000) Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sanguinis 78, 7 12.
4. Azzi, A., Ciappi, S., Zakvrzewska, K., Morfini, M., Mariani, G. Mannucci, P.M 1992) Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. American Journal of Hematology 39, 228 230.
5. Azzi, A., Morfini, M. Mannucci, P.M 1999) The transfusion-associated transmission of parvovirus B19. Transfusion Medicine Reviews 13, 194 204.
6. Azzi, A., Maggi, F., Zakrzewska, K. et al 2006) Different behavior of erythrovirus B19 and torquetenovirus in response to a single step of albumin purification. Transfusion 46, 1162 1167.
7. Ballou, W.R., Reed, J.L., Noble, W., Young, N.S. Koenig, S 2003) Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. Journal of Infectious Diseases 187, 675 678.
8. Bansal, G.P., Hatfield, J.A., Dunn, F.E. et al 1993) Candidate recombinant vaccine for human B19 parvovirus. Journal of Infectious Diseases 167, 1034 1044.
9. Baylis, S.A., Shah, N. Minor, P.D 2004) Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma. Journal of Virological Methods 121, 7 16.
10. Behzad-Behbahani, A., Pouransari, R., Tabei, S.Z. et al 2005) Risk of viral transmission via bone marrow progenitor cells versus umbilical cord blood hematopoietic stem cells in bone marrow transplantation. Transplantation Proceedings 37, 3211 3212.
11. Blaeser, F., Kelly, M., Siegrist, K. et al 2005) Critical function of the CD40 pathway in parvovirus B19 infection revealed by a hypomorphic CD40 ligand mutation. Clinical Immunology 117, 231 237.
12. Blumel, J., Schmidt, I., Effenberger, W. et al 2002a) Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 42, 1473 1481.
13. Blumel, J., Schmidt, I., Willkommen, H. Lower, J 2002b) Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 42, 1011 1018.
14. Blumel, J., Eis-Hubinger, A.M., Stuhler, A., Bonsch, C., Gessner, M. Lower, J 2005) Characterization of parvovirus B19 genotype 2 in KU812Ep6 cells. Journal of Virology 79, 14197 206.
15. Bluth, M.H., Norowitz, K.B., Chice, S., Shah, V.N., Nowakowski, M., Durkin, H.G. Smith-Norowitz, T.A 2005) IgE, CD8(+)CD60+ T cells and IFN-alpha in human immunity to parvovirus B19 in selective IgA deficiency. Human Immunology 66, 1029 1038.
16. Bonvicini, F., Filippone, C., Manaresi, E., Gentilomi, G.A., Zerbini, M., Musiani, M. Gallinella, G 2006) Peptide nucleic acid-based in situ hybridization assay for detection of parvovirus B19 nucleic acids. Clinical Chemistry 52, 973 978.
17. Boschetti, N., Niederhauser, I., Kempf, C., Stuhler, A., Lower, J. Blumel, J 2004) Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion 44, 1079 1086.
18. Braham, S., Gandhi, J., Beard, S. Cohen, B 2004) Evaluation of the Roche LightCycler parvovirus B19 quantification kit for the diagnosis of parvovirus B19 infections. Journal of Clinical Virology 31, 5 10.
19. Broliden, K 2001) Parvovirus B19 infection in pediatric solid-organ and bone marrow transplantation. Pediatric Transplantation 5, 320 330.
20. Brown, K.E., Green, S.W., Antunez de Mayolo, J., Bellanti, J.A., Smith, S.D., Smith, T.J. Young, N.S 1994) Congenital anaemia after transplacental B19 parvovirus infection. Lancet 343, 895 896.
21. Brown, K.E., Young, N.S., Alving, B.M. Barbosa, L.H 2001) Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 41, 130 135.
22. Butchko, A.R. Jordan, J.A 2004) Comparison of three commercially available serologic assays used to detect human parvovirus B19-specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women. Journal of Clinical Microbiology 42, 3191 3195.
23. Candotti, D., Etiz, N., Parsyan, A. Allain, J.P 2004) Identification and characterization of persistent human erythrovirus infection in blood donor samples. Journal of Virology 78, 12169 12178.
24. Cassinotti, P. Siegl, G 2000) Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual. European Journal of Clinical Microbiology & Infectious Diseases 19, 886 887.
25. Cassinotti, P., Siegl, G., Michel, B.A. Bruhlmann, P 1998) Presence and significance of human parvovirus B19 DNA in synovial membranes and bone marrow from patients with arthritis of unknown origin. Journal of Medical Virology 56, 199 204.
26. Cohen, B.J., Beard, S., Knowles, W.A. et al 1997) Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Transfusion 37, 947 952.
27. Cohen, B.J., Gandhi, J. Clewley, J.P 2006) Genetic variants of parvovirus B19 identified in the United Kingdom: implications for diagnostic testing. Journal of Clinical Virology 36, 152 155.
28. Corbin, F. 3rd. (2002) Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer. International Journal of Hematology 76 (Suppl. 2 253 257.
29. Cossart, Y.E., Field, A.M., Cant, B. Widdows, D 1975) Parvovirus-like particles in human sera. Lancet 1, 72 73.
30. Council of Europe (CE)-European Directorate for the Quality of Medicines (EDQM) (2007) European Pharmacopoeia (5th edn), Supplement 5.6. TSO, London.
31. Daly, P., Corcoran, A., Mahon, B.P. Doyle, S 2002) High-sensitivity PCR detection of parvovirus B19 in plasma. Journal of Clinical Microbiology 40, 1958 1962.
32. Davenport, R., Geohas, G., Cohen, S., Beach, K., Lazo, A., Lucchesi, K. Pehta, J 2000) Phase IV study of Plas+®SD: hepatitis A (HAV) and parvovirus B19 (B19) safety results. Blood 96, 1942.
33. Dorsch, S., Liebisch, G., Kaufmann, B., von Landenberg, P., Hoffmann, J.H., Drobnik, W. Modrow, S 2002) The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. Journal of Virology 76, 2014 2018.
34. Doyle, S. Corcoran, A 2006) The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals. Journal of Infectious Diseases 194, 154 158.
35. Eis-Hubinger, A.M., Oldenburg, J., Brackmann, H.H., Matz, B. Schneweis, K.E 1996) The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. Zentralblatt für Bakteriologie 284, 232 240.
36. Ennis, O., Corcoran, A., Kavanagh, K., Mahon, B.P. Doyle, S 2001) Baculovirus expression of parvovirus B19 (B19V) NS1: utility in confirming recent infection. Journal of Clinical Virology 22, 55 60.
37. Erdman, D.D., Anderson, B.C., Torok, T.J., Finkel, T.H. Anderson, L.J 1997) Possible transmission of parvovirus B19 from intravenous immune globulin. Journal of Medical Virology 53, 233 236.
38. Farrugia, A 2003) Risk of parvovirus infection by immunoglobulin. British Journal of Haematology 121, 955 956 author reply 956.
39. Fattet, S., Cassinotti, P. Popovic, M.B 2004) Persistent human parvovirus B19 infection in children under maintenance chemotherapy for acute lymphocytic leukemia. Journal of Pediatric Hematology/Oncology 26, 497 503.
40. Franssila, R., Auramo, J., Modrow, S. et al 2005) T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity. Clinical and Experimental Immunology 142, 53 61.
41. Frickhofen, N., Abkowitz, J.L., Safford, M. et al 1990) Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Annals of Internal Medicine 113, 926 933.
42. Gallinella, G., Manaresi, E., Venturoli, S., Grazi, G.L., Musiani, M. Zerbini, M 1999) Occurrence and clinical role of active parvovirus B19 infection in transplant recipients. European Journal of Clinical Microbiology & Infectious Diseases 18, 811 813.
43. Groeneveld, K. van der Noordaa, J 2003) Blood products and parvovirus B19. Netherlands Journal of Medicine 61, 154 156.
44. Grosse-Bley, A., Eis-Hubinger, A.M., Kaiser, R., Oldenburg, J., Brackmann, H.H., Schwarz, T.F. Schneweis, K.E 1994) Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs. Thrombosis and Haemostasis 72, 503 507.
45. Hayakawa, F., Imada, K., Towatari, M. Saito, H 2002) Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. British Journal of Haematology 118, 1187 1189.
46. Heegaard, E.D. Brown, K.E 2002) Human parvovirus B19. Clinical Microbiology Reviews 15, 485 505.
47. Heegaard, E.D. Laub Petersen, B 2000) Parvovirus B19 transmitted by bone marrow. British Journal of Haematology 111, 659 661.
48. Heegaard, E.D., Panum Jensen, I. Christensen, J 2001) Novel PCR assay for differential detection and screening of erythrovirus B19 and erythrovirus V9. Journal of Medical Virology 65, 362 367.
49. Heegaard, E.D., Petersen, B.L., Heilmann, C.J. Hornsleth, A 2002a) Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. Journal of Clinical Microbiology 40, 933 936.
50. Heegaard, E.D., Qvortrup, K. Christensen, J 2002b) Baculovirus expression of erythrovirus V9 capsids and screening by ELISA: serologic cross-reactivity with erythrovirus B19. Journal of Medical Virology 66, 246 252.
51. Hino, M., Ishiko, O., Honda, K.I., Yamane, T., Ohta, K., Takubo, T. Tatsumi, N 2000) Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery. British Journal of Haematology 108, 194 195.
52. Hitzler, W.E. Runkel, S 2002) Prevalence of human parvovirus B19 in blood donors as determined by a haemagglutination assay and verified by the polymerase chain reaction. Vox Sanguinis 82, 18 23.
53. Hokynar, K., Soderlund-Venermo, M., Pesonen, M., Ranki, A., Kiviluoto, O., Partio, E.K. Hedman, K 2002) A new parvovirus genotype persistent in human skin. Virology 302, 224 228.
54. Hokynar, K., Norja, P., Laitinen, H. et al 2004) Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests. Journal of Clinical Microbiology 42, 2013 2019.
55. Isa, A., Norbeck, O., Hirbod, T. et al 2006) Aberrant cellular immune responses in humans infected persistently with parvovirus B19. Journal of Medical Virology 78, 129 133.
56. Jordan, J., Tiangco, B., Kiss, J. Koch, W 1998) Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sanguinis 75, 97 102.
57. Jordan, J.A 2000) Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia coli-based VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women. Journal of Clinical Microbiology 38, 1472 1475.
58. Kaufmann, B., Simpson, A.A. Rossmann, M.G 2004) The structure of human parvovirus B19. Proceedings of the National Academy of Sciences of the U S A 101, 11628 11633.
59. Kerr, J.R. Cunniffe, V.S 2000) Antibodies to parvovirus B19 non-structural protein are associated with chronic but not acute arthritis following B19 infection. Rheumatology (Oxford) 39, 903 908.
60. Kerr, S., O'Keeffe, G., Kilty, C. Doyle, S 1999) Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. Journal of Medical Virology 57, 179 185.
61. Kreil, T.R., Wieser, A., Berting, A. et al 2006) Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives. Transfusion 46, 1143 1151.
62. Kurtzman, G., Frickhofen, N., Kimball, J., Jenkins, D.W., Nienhuis, A.W. Young, N.S 1989a) Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. New England Journal of Medicine 321, 519 23.
63. Kurtzman, G.J., Cohen, B.J., Field, A.M., Oseas, R., Blaese, R.M. Young, N.S 1989b) Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 84, 1114 1123.
64. LaMonte, A.C., Paul, M.E., Read, J.S., Frederick, M.M., Erdman, D.D., Han, L.L. Anderson, L.J 2004) Persistent parvovirus B19 infection without the development of chronic anemia in HIV-infected and -uninfected children: the Women and Infants Transmission Study. Journal of Infectious Diseases 189, 847 851.
65. Laurian, Y., Dussaix, E., Parquet, A., Chalvon-Demersay, A., d'Oiron, R. Tchernia, G 1994) Transmission of human parvovirus B19 by plasma derived factor VIII concentrates. Nouvelle revue française d'hématologie 36, 449 453.
66. Lazo, A., Tassello, J., Jayarama, V. et al 2002) Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry. Vox Sanguinis 83, 313 323.
67. Lefrere, J.J., Servant-Delmas, A., Candotti, D. et al 2005) Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 106, 2890 2895.
68. Lin, L., Hanson, C.V., Alter, H.J. et al 2005) Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 45, 580 590.
69. Llewelyn, C. Williamson, L 2004) Distribution of blood components recipients according to immune status. Euro Sat, October 19-20.
70. Lyon, D.J., Chapman, C.S., Martin, C., Brown, K.E., Clewley, J.P., Flower, A.J. Mitchell, V.E 1989) Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate. Lancet 1, 1085.
71. Manaresi, E., Gallinella, G., Zerbini, M., Venturoli, S., Gentilomi, G. Musiani, M 1999) IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay. Journal of Medical Virology 57, 174 178.
72. Manaresi, E., Gallinella, G., Morselli Labate, A.M., Zucchelli, P., Zaccarelli, D., Ambretti, S., Delbarba, S., Zerbini, M. Musiani, M 2004a). Seroprevalence of IgG against conformational and linear capsid antigens of parvovirus B19 in Italian blood donors. Epidemiol Infect 132, 857 62.
73. Manaresi, E., Gallinella, G., Venturoli, S., Zerbini, M. Musiani, M 2004b). Detection of parvovirus B19 IgG: choice of antigens and serological tests. Journal of Clinical Virology 29, 51 3.
74. Mariani, G., Di Paolantonio, T., Baklaya, R., Morfini, M. Mannucci, P.M 1993) Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione dell'Emofilia. Transfusion 33, 814 818.
75. Matsui, H., Sugimoto, M., Tsuji, S., Shima, M., Giddings, J. Yoshioka, A 1999) Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate. Journal of Pediatric Hematology/Oncology 21, 74 76.
76. Mauser-Bunschoten, E.P., Zaaijer, H.L., van Drimmelen, A.A., de Vries, S., Roosendaal, G., van den Berg, H.M. Lelie, P.N 1998) High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients. Vox Sanguinis 74, 225 227.
77. McOmish, F., Yap, P.L., Jordan, A., Hart, H., Cohen, B.J. Simmonds, P 1993) Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. Journal of Clinical Microbiology 31, 323 328.
78. Miyagawa, E., Yoshida, T., Takahashi, H. et al 1999) Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity. Journal of Virological Methods 83, 45 54.
79. Moudgil, A., Shidban, H., Nast, C.C. et al 1997) Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 64, 1847 1850.
80. Munakata, Y., Saito-Ito, T., Kumura-Ishii, K. et al 2005) Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 106, 3449 3456.
81. Murer, L., Zacchello, G., Bianchi, D. et al 2000) Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. Journal of the American Society of Nephrology 11, 1132 1137.
82. Norja, P., Hokynar, K., Aaltonen, L.M. et al 2006) Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proceedings of the National Academy of Sciences of the U S A 103, 7450 7453.
83. Parkkinen, J., Rahola, A., von Bonsdorff, L., Tolo, H. Torma, E 2006) A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance. Vox Sanguinis 90, 97 104.
84. Parsyan, A., Addo-Yobo, E., Owusu-Ofori, S., Akpene, H., Sarkodie, F. Allain, J.-P. (2006a) Effects of transfusion on human erythrovirus B19 susceptible or infected pediatric recipients in a genotype 3 endemic area (in press). Transfusion 46, 1593 1600.
85. Parsyan, A., Kerr, S., Owusu-Ofori, S., Elliott, G. Allain, J.P 2006b) Reactivity of genotype-specific recombinant proteins of human erythrovirus B19 with plasmas from areas where genotype 1 or 3 is endemic. Journal of Clinical Microbiology 44, 1367 1375.
86. Peerlinck, K., Goubau, P., Reybrouck, R., Desmyter, J. Vermylen, J 1995) Parvovirus B19 antibodies in patients with haemophilia A. Thrombosis and Haemostasis 73, 555 556.
87. Pruss, A., Kao, M., Gohs, U., Koscielny, J., von Versen, R. Pauli, G 2002) Effect of gamma irradiation on human cortical bone transplants contaminated with enveloped and non-enveloped viruses. Biologicals 30, 125 133.
88. Purmal, A., Valeri, C.R., Dzik, W., Pivacek, L., Ragno, G., Lazo, A. Chapman, J 2002) Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies. Transfusion 42, 139 145.
89. Rollag, H., Patou, G., Pattison, J.R., Degre, M., Evensen, S.A., Froland, S.S. Glomstein, A 1991) Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scandinavian Journal of Infectious Diseases 23, 675 679.
90. Ruane, P.H., Edrich, R., Gampp, D., Keil, S.D., Leonard, R.L. Goodrich, R.P 2004) Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 44, 877 885.
91. Sakata, H., Ihara, H., Sato, S., Kato, T., Ikeda, H. Sekiguchi, S 1999) Efficiency of donor screening for human parvovirus B19 by the receptor-mediated hemagglutination assay method. Vox Sanguinis 77, 197 203.
92. Saldanha, J 2001) Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products. Journal of Clinical Virology 20, 7 13.
93. Sanabani, S., Neto, W.K., Pereira, J. Sabino, E.C 2006) Sequence variability of human erythroviruses present in bone marrow of Brazilian patients with various parvovirus B19-related hematological symptoms. Journal of Clinical Microbiology 44, 604 606.
94. Santagostino, E., Mannucci, P.M., Gringeri, A., Azzi, A. Morfini, M 1994) Eliminating parvovirus B19 from blood products. Lancet 343, 798.
95. Santagostino, E., Mannucci, P.M., Gringeri, A. et al 1997) Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion 37, 517 522.
96. Sato, H., Takakura, F., Kojima, E., Fukada, K., Okochi, K. Maeda, Y 1995) Screening of blood donors for human parvovirus B19. Lancet 346, 1237 1238.
97. Sato, K., Matsuda, E., Kamisango, K., Iwasaki, H., Matsubara, S. Matsunaga, Y 2000) Development of a hypersensitive detection method for human parvovirus B19 DNA. Journal of Clinical Microbiology 38, 1241 1243.
98. Schmidt, I., Blumel, J., Seitz, H., Willkommen, H. Lower, J 2001) Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sanguinis 81, 228 235.
99. Schwarz, T.F., Serke, S., Hottentrager, B. et al 1992) Replication of parvovirus B19 in hematopoietic progenitor cells generated in vitro from normal human peripheral blood. Journal of Virology 66, 1273 1276.
100. Searle, K., Schalasta, G. Enders, G 1998) Development of antibodies to the nonstructural protein NS1 of parvovirus B19 during acute symptomatic and subclinical infection in pregnancy: implications for pathogenesis doubtful. Journal of Medical Virology 56, 192 198.
101. Servant, A., Laperche, S., Lallemand, F., Marinho, V., De Saint Maur, G., Meritet, J.F. Garbarg-Chenon, A 2002) Genetic diversity within human erythroviruses: identification of three genotypes. Journal of Virology 76, 9124 9134.
102. Shackelton, L.A. Holmes, E.C 2006) Phylogenetic evidence for the rapid evolution of human b19 erythrovirus. Journal of Virology 80, 3666 3669.
103. Shimomura, S., Komatsu, N., Frickhofen, N., Anderson, S., Kajigaya, S. Young, N.S 1992) First continuous propagation of B19 parvovirus in a cell line. Blood 79, 18 24.
104. Srivastava, C.H., Zhou, S., Munshi, N.C. Srivastava, A 1992) Parvovirus B19 replication in human umbilical cord blood cells. Virology 189, 456 461.
105. Suikkanen, S., Antila, M., Jaatinen, A., Vihinen-Ranta, M. Vuento, M 2003) Release of canine parvovirus from endocytic vesicles. Virology 316, 267 280.
106. Takahashi, T., Ozawa, K., Takahashi, K., Asano, S. Takaku, F 1990) Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation. Blood 75, 603 610.
107. Terpstra, F.G., Parkkinen, J., Tolo, H. et al 2006) Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product. Vox Sanguinis 90, 21 32.
108. Thomas, I., Di Giambattista, M., Gerard, C. et al 2003) Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins. Vox Sanguinis 84, 300 307.
109. Tsujimura, M., Matsushita, K., Shiraki, H., Sato, H., Okochi, K. Maeda, Y 1995) Human parvovirus B19 infection in blood donors. Vox Sanguinis 69, 206 212.
110. Wakamatsu, C., Takakura, F., Kojima, E. et al 1999) Screening of blood donors for human parvovirus B19 and characterization of the results. Vox Sanguinis 76, 14 21.
111. Weigel-Kelley, K.A., Yoder, M.C. Srivastava, A 2003) Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood 102, 3927 3933.
112. Williams, M.D., Cohen, B.J., Beddall, A.C., Pasi, K.J., Mortimer, P.P. Hill, F.G 1990) Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sanguinis 58, 177 181.
113. Wong, S., Young, N.S. Brown, K.E 2003) Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis-associated aplastic anemia. Journal of Infectious Diseases 187, 1581 1586.
114. Woolf, A.D. Cohen, B.J 1995) Parvovirus B19 and chronic arthritis - causal or casual association? Annals of the Rheumatic Diseases 54, 535 536.
115. Wu, C.G., Mason, B., Jong, J. et al 2005) Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion 45, 1003 1010.
116. Yaegashi, N., Shiraishi, H., Takeshita, T., Nakamura, M., Yajima, A. Sugamura, K 1989) Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver. Journal of Virology 63, 2422 2426.
117. Yaegashi, N., Niinuma, T., Chisaka, H. et al 1998) The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. Journal of Infection 37, 28 35.
118. Yango, A. Jr., Morrissey, P., Gohh, R. Wahbeh, A 2002) Donor-transmitted parvovirus infection in a kidney transplant recipient presenting as pancytopenia and allograft dysfunction. Transplant Infectious Disease 4, 163 166.
119. Yee, T.T., Lee, C.A. Pasi, K.J 1995) Life-threatening human parvovirus B19 infection in immunocompetent haemophilia. Lancet 345, 794 795.
120. Yee, T.T., Cohen, B.J., Pasi, K.J. Lee, C.A 1996) Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. British Journal of Haematology 93, 457 459.
121. Yokoyama, T., Murai, K., Murozuka, T., Wakisaka, A., Tanifuji, M., Fujii, N. Tomono, T 2004) Removal of small non-enveloped viruses by nanofiltration. Vox Sanguinis 86, 225 229.
122. Yoto, Y., Kudoh, T., Haseyama, K. et al 1995) Incidence of human parvovirus B19 DNA detection in blood donors. British Journal of Haematology 91, 1017 1018.
123. Yunoki, M., Tsujikawa, M., Urayama, T. et al 2003) Heat sensitivity of human parvovirus B19. Vox Sanguinis 84, 164 169.
124. Yunoki, M., Urayama, T., Tsujikawa, M., Sasaki, Y., Abe, S., Takechi, K. Ikuta, K 2005) Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations. British Journal of Haematology 128, 401 404.
125. Zaaijer, H.L., Koppelman, M.H. Farrington, C.P 2004) Parvovirus B19 viraemia in Dutch blood donors. Epidemiology and Infection 132, 1161 1166.
126. Zakrzewska, K., Azzi, A., Patou, G., Morfini, M., Rafanelli, D. Pattison, J.R 1992) Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction. British Journal of Haematology 81, 407 412.
127. Zanella, A., Rossi, F., Cesana, C. et al 1995) Transfusion-transmitted human parvovirus B19 infection in a thalassemic patient. Transfusion 35, 769 772.
128. Zhi, N., Mills, I.P., Lu, J., Wong, S., Filippone, C. Brown, K.E 2006) Molecular and functional analyses of a human parvovirus B19 infectious clone demonstrates essential roles for NS1, VP1, and the 11-kilodalton protein in virus replication and infectivity. Journal of Virology 80, 5941 5950.